PDGFRA and gastrointestinal stromal tumor: c-KIT mutations (2, 10) followed by platelet-derived growth factor receptor alpha (PDGFRA) mutations (11) were discovered and small molecule targeted therapies with tyrosine kinase inhibitors (12, 13) were developed in GIST.